Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Infectious Skin DiseasesBacterial Skin DiseasesStaphylococcal Skin InfectionsStreptococcal InfectionsAbscess
Interventions
DRUG

Radezolid

450mg PO QD

DRUG

Radezolid

450mg PO BID

DRUG

Linezolid

600mg PO BID

Trial Locations (19)

Unknown

Drug Research & Analysis Corp, Montgomery

OWENS Pharma Research Center, Long Beach

Healthcare Partners Medical Group, Los Angeles

HealthCare Partners Medical Group, Pasadena

Olive View- UCLA Center, Dept. Emergency Medicine, Sylmar

South Florida Clinical Research, Atlantis

Southeast Regional Research Group, Columbus

Contemporary Medicine, LLC, Hinesville

Infectious Disease of Indiana, PSC., Indianapolis

Clinical Trials of America, Inc., Shreveport

Arnold Markowitz, MD., PC, Keego Harbor

Mercury Street Medical Group, LLC, Butte

Jamaica Hospital Medical Center, Jamaica

ALL-TRIALS Clinical Research, LLC, Winston-Salem

Summa Health System, Akron

Brandywine Clinical Research, Downington

Warminster Medical Associates, P.C., Warminster

McKenzie Medical Center, McKenzie

J. Lewis Research, Inc., Salt Lake City

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY

NCT00646958 - Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections | Biotech Hunter | Biotech Hunter